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Hepatocellular adenoma (HCA) is defined as a benign mono-
clonal proliferation of hepatocytes [1]. It is more prevalent in 
Western countries, with an incidence of 3–4 cases/100,000 in 
Europe and North America [1], and its incidence is much lower 
in Asian countries [2-6]. Since the first characterization of the 
molecular subtypes of HCAs in 2006 [7], HCA has now become 
an increasingly heterogeneous entity, and this has brought a 
strong translational impact for pathologists (Table 1) [8-10]. In 
this review, we will summarize the clinicopathological and molec-
ular characteristics of the various subtypes of HCA, and discuss the 
various pitfalls in the pathological diagnosis of HCA. 
GENERAL CLINICOPATHOLOGICAL FEATURES 
OF HEPATOCELLULAR ADENOMA 
The typical patient is female and of reproductive age (15–50 
years), while HCAs are relatively rare in men, children and elderly 
patients (> 65 years). The major risk factors for HCA include oral 
contraceptive use, obesity, metabolic syndrome, alcohol intake 
and use of anabolic steroids. Other conditions associated with 
HCA development include glycogen storage diseases (especially 
types 1 and 3), galactosemia, tyrosinemia, familial polyposis coli, 
polycystic ovary syndrome and β-thalassemia. Interestingly, a 
few series from Asian countries have demonstrated a higher inci-
dence of HCA in men, and the incidence of oral contraceptive use 
was lower in female patients [2,3,5]. The main clinical implica-
tions of HCA include the risk of bleeding, especially in larger 
tumors, and the risk of malignant transformation to hepatocel-
lular carcinoma (HCC). The risk of HCC development depends 
on the subtype, being the highest in β-catenin-activated HCAs 
(B-HCAs). The general indications for surgical management of 
HCAs include male gender, large size (>5 cm), interval growth 
during follow up on imaging, and atypical pathological features 
(e.g., atypical cytoarchitectural features, presence of β-catenin 
activation).
In general, HCAs are grossly well demarcated but non-encap-
sulated, and the color varies from pale yellow-tan to bile-stained 
depending on the histology. Hemorrhage or peliosis may be pres-
ent. HCAs are more frequently solitary lesions; however, multiple 
HCAs may occur, and the term “adenomatosis” is used when 
there are 10 or more HCAs. In cases of multiple HCAs, most cases 
demonstrate multiple HCAs of the same molecular subtype, 
although some tumors from the same patient may belong to dif-
ferent subgroups of HCA [11]. The size is variable, ranging from 
1cm to as large as 30 cm. Unlike HCCs, the background liver is 
typically non-cirrhotic, although advanced stage fibrosis may be 
present in the setting of alcoholic liver disease, metabolic syndrome 
or vascular disorders. Histologically, the tumor cells resemble he-
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Table 1. Summary of the clinicopathological and molecular characteristics of different HCA subtypes
Subtype (frequency, %)
Characteristic features
Molecular Clinical Histopathological Immunohistochemical
HNF1A-inactivated HCA 
(30%–40%)
HNF1A inactivating mutations 
(germline 10%, somatic 90%)
Female, obesity, MODY3, 
adenomatosis
Diffuse steatosis LFABP expression loss
Inflammatory HCA 
(40%–50%)
gp130/IL6ST, FRK, STAT3, GNAS, 
JAK1 mutations














CTNNB1 exon 3 activating 
mutations
Male, young age, anabolic 
steroids, glycogen storage 









CTNNB1 exon 7 or 8 activating 
mutations
Low risk of HCC 
transformation







gp130/IL6ST, STAT3, FRK, GNAS, 
JAK1 mutations + CTNNB1 exon 
3 or 7/8 mutations
Similar to inflammatory HCA
Increased risk of HCC 
transformation (ex.3)





Nuclear β-catenin, diffuse 
strong GS expression (ex.3)
Sonic hedgehog–
activated HCA (4%)
INHBE-GLI1 fusion, resulting 
in sonic hedgehog pathway 
activation
Obesity, hemorrhage Hemorrhage PTGDS, ASS1
Unclassified HCA (< 7%) Unknown - - -
HCA, hepatocellular adenoma; MODY3, maturity-onset diabetes type 3; LFABP, liver fatty acid binding protein; SAA, serum amyloid A; CRP, C-reactive pro-
tein; HCC, hepatocellular carcinoma; GS, glutamine synthetase; PTGDS, prostaglandin D2 synthase; ASS1, argininosuccinate synthase 1.
patocytes, demonstrating eosinophilic or clear cytoplasm, and they 
are arranged in thin trabeculae. Portal tracts are absent, and thin-
walled vascular channels and small arteriolar structures are seen. 
RECENT UPDATES ON THE CLASSIFICATION 
OF HEPATOCELLULAR ADENOMA 
Inflammatory HCA
Inflammatory HCA (IHCA) is the most common subtype 
(40%–50%) of HCAs, and demonstrates constitutive activation 
of the interleukin-6/JAK/STAT pathway. Molecular alterations 
include mutations in gp130/IL6ST (50%), FRK (10%), STAT3 
(5%), GNAS (5%), ROS1 (3%), and JAK1 (1%). The main risk 
factors for IHCA include obesity, metabolic syndrome and alcohol 
intake. 
The main histological features include foci of inflammation, 
thick arteries, and sinusoidal dilatation (Fig. 1). Congestion, 
hemorrhage and peliosis may be present. Portal tracts are absent; 
however, ductular reaction and pseudoportal tracts are frequently 
seen. Steatosis may be observed and is usually focal. The back-
ground liver frequently demonstrates steatosis, which may be 
attributed to the patient’s underlying risk factors (obesity, met-
abolic syndrome, alcoholic liver disease etc.). 
Immunohistochemistry for serum amyloid A (SAA) and C-
reactive protein (CRP) may provide important diagnostic clues, 
as IHCA is characterized by the overexpression of these acute 
phase reactants via STAT3 activation. SAA and/or CRP expres-
sion in IHCA is usually diffuse and strong, and sharply demar-
cated from the surrounding liver parenchyme. However, it should 
be noted that the adjacent liver may be focally or even diffusely 
positive for SAA and/or CRP in some cases, especially when there 
is marked inflammation or hemorrhage in the background liver, 
and in the setting of previous embolization [12]. Therefore, the 
histological context should be taken into account when inter-
preting SAA/CRP stains and it is important that the staining 
results are compared with the background liver, preferably also 
with positive control tissues. 
Importantly, about 10% of IHCA also demonstrate muta-
tions in CTNNB1 (B-IHCA, “mixed” HCA). Although the 
risk for HCC transformation is generally low in IHCA, the con-
currence of strong β-catenin activation in IHCAs increases the 
risk of HCC development. Therefore, the addition of β-catenin 
and glutamine synthetase (GS) immunohistochemistry is also 
necessary, in order to identify mixed HCAs (B-IHCA). B-HCAs 
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are described in more detail in the following section.
β-catenin–activated HCA
Approximately 10% of HCAs demonstrate CTNNB1 muta-
tions/deletions leading to different levels of β-catenin pathway 
activation. These tumors are designated as B-HCA. CTNNB1 al-
terations most often occur in exon 3 (7%, Bex3-HCA) or in exons 
7 and 8 (3%, Bex7,8-HCA). Mutations or large deletions in exon 
3 most frequently involve the β-Trcp consensus site (D32–S37, 
also known as the exon 3 hotspot) and these are associated with 
high levels of β-catenin activation and high risk of HCC trans-
formation [13,14]. Outside of the β-Trcp consensus site, T41 
and S45 mutations in exon 3 have also been frequently demon-
strated, and these are associated with moderate to weak levels of 
β-catenin activation. In contrast, mutations in CTNNB1 exon 
7 (K335) and exon 8 (W383, R386, and N387) result in weak 
β-catenin activation. The clinical and histopathological features 
of Bex7,8-HCA are still unclear, although the risk of HCC devel-
opment appear to be low in these tumors, unlike the Bex3-HCAs 
[10,13,14]. CTNNB1 alterations may also occur in a subset of 
IHCAs (B-IHCA or “mixed” HCA, 5%–10%).
The characteristic clinical features associated with Bex3-HCAs 
include male gender, a history of androgen administration and 
underlying glycogen storage disease. These tumors are usually 
solitary and rarely multiple. Mild cytological atypia may be ob-
served in Bex3-HCAs, and architectural atypia, including mild 
trabecular thickening, small cell change or pseudoglandular 
structures, is also frequently seen (Fig. 2). Bile or lipofuscin 
pigments are frequently observed in the tumor cells; the lipofus-
cin pigmentation may be very prominent in some HCAs [15]. 
Most importantly, as Bex3-HCAs are associated with high risk of 
malignant transformation to HCC, the practical implication of 
this subtype of HCA is in excluding the possibility of well-differ-




Fig. 1. Inflammatory hepatocellular adenoma. Sinusoidal dilatation, congestion and peliosis is seen in the tumor (A–C). Inflammatory cell infil-
tration (C), thick arteriolar structures with ductular reaction, resembling portal tracts (“pseudo-portal tracts”) and steatosis (D) may be seen in 
these tumors. Diffuse steatosis may be seen in the background liver (A). The tumor cells express serum amyloid A (E; inset: granular cyto-
plasmic staining in tumor cells) and C-reactive peptide (F).
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Although direct sequencing of the CTNNB1 gene would be 
the most definitive means of characterizing the molecular sub-
type of a presumed B-HCA, this is not feasible in most clinical 
practices. Fortunately, immunohistochemical stains for β-catenin 
and GS have been demonstrated to be good surrogate markers 
reflecting CTNNB1 status. Nuclear β-catenin expression and dif-
fuse strong homogeneous GS expression are the typical immuno-
histochemical features of B-HCAs with strong β-catenin activa-
tion (non-S45 Bex3-HCA). Interestingly, GS expression patterns 
have been recently demonstrated to reflect the mutational status 
of CTNNB1 (Fig. 3). Diffuse homogeneous expression (strong 
GS expression in > 90% of tumor cells) has been demonstrated 
in Bex3-HCAs with mutations or large deletions in the D32–S37 
hotspot of CTNNB1 exon 3 (β-Trcp consensus site). In contrast, 
Bex3-HCAs with CTNNB1 exon 3 T41 or S45 mutations, which 
have been associated with moderate β-catenin activation, dem-
onstrate diffuse heterogeneous GS expression (50%–90% of tu-
mor cells expressing GS in a starry-sky pattern). Bex7,8-HCAs lack 
the immunohistochemical features of strong β-catenin activation 
(i.e., diffuse strong GS expression, nuclear β-catenin expression). 
Weak patchy GS staining in addition to the “normal” perivenular 
pattern has been frequently seen in association with weak β-catenin 
activation (absent or rare nuclear β-catenin), which is common in 
Bex7,8-HCAs, but also rarely seen in Bex3-HCAs with S45 muta-
tions. Interestingly, GS accentuation and discontinuous band-like 
GS staining at the tumor border has been described in Bex3-HCAs 
with S45 mutations and Bex7,8-HCAs, respectively [16,17]. These 
expression patterns are different from the “map-like” GS pattern 
of focal nodular hyperplasia (FNH), which is described later. In 
contrast, GS expression in the normal liver has a perivenular dis-
tribution (“normal” pattern), where GS expression is limited to 1 




Fig. 2. β-catenin–activated hepatocellular adenoma (B-HCA). There is mild trabecular thickening (A) and pseudoglandular structures (B, C). 
Mild cytological atypia is present (A–C). Cholestasis may be seen (C). On immunohistochemistry, B-HCA with strong β-catenin activation 
(Bex3-HCA) demonstrates nuclear β-catenin expression (D), instead of the normal membranous pattern (inset), and diffuse homogeneous 
glutamine synthetase expression is seen in such tumors (E, inset: higher-power view).
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HNF1A-inactivated HCA
HNF1A-inactivated HCAs (H-HCA) constitute 30%–35% 
of HCAs and are characterized by inactivating mutations in 
HNF1A, which encodes hepatocyte nuclear factor 1α. In the 
majority (90%) of H-HCAs, the HNF1A mutation is somatic 
and biallelic, while the remaining 10% comprise H-HCAs with 
germline HNF1A mutations. The latter is frequently associated 
with maturity-onset diabetes type 3 (MODY3) and the presence 
of adenomatosis. H-HCAs have also been reported in the back-
ground of vascular abnormalities and congenital hepatic fibrosis 
[18-20].
Histologically, H-HCAs typically demonstrate diffuse steatosis 
in the tumor cells (Fig. 4), although some cases may show mini-
mal or no steatosis, especially those arising in hepatic vascular 
disorders [20,21]. The tumor cells demonstrate no significant 
nuclear atypia and they are usually arranged in thin trabeculae, 
although occasional pseudoglandular structures may be observed. 
Inflammatory cell infiltration is not a characteristic of H-HCA. 
Immunohistochemically, the tumor cells demonstrate loss of liver 
fatty acid binding protein (LFABP) expression. H-HCAs dem-
onstrate a low risk of HCC transformation compared to other 
types.
Unclassified HCA and sonic hedgehog–activated HCA
By definition, unclassified HCA (U-HCA) lacks the charac-
teristics of other subtypes. The frequency of U-HCA (5%–10%) 
is decreasing, as HCAs belonging to this group are being increas-
ingly characterized as specific subtypes. Sonic hedgehog-acti-
vated HCA (sh-HCA) is an emerging subtype of HCA with 
distinct clinicopathological features, including increased bleeding 
risk. sh-HCA has been demonstrated to account for ~4% of 
HCAs that were previously classified as U-HCA [10]. Molecular 
features of sh-HCA include INBHE-GLI1 fusion and overex-
pression of GLI1, which is the key transcription factor of the sonic 
hedgehog pathway. Recently, potential surrogate immunohisto-













Exon 3 D32–S37, 
  T41 mutation or 




Exon 3 S45 mutation
Focal or absent
Diffuse 
  heterogeneous or 
  weak/patchy 
Strong band-like 
  expression at border
Exon 7, 8 mutation
Absent
Weak/patchy 
  perivenular pattern
Glutamine 
  synthetase 
  expression
FNH β-catenin-activated HCAa
Fig. 3. Immunohistochemical correlates of CTNNB1 alteration status in β-catenin-activated HCA, FNH and normal liver. FNH, focal nodular 
hyperplasia; HCA, hepatocellular adenoma. aSerum amyloid A and/or reactive peptide is additionally expressed in β-catenin-activated inflam-
matory HCA. 
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lipocalin-type prostaglandin D2 synthase and argininosuccinate 
synthase 1 [22-25]. 
COMMON PRACTICAL ISSUES 
FOR PATHOLOGISTS
Atypia in HCAs: HCCs or atypical hepatocellular neoplasms?
In practice, pathologists are often faced with having to distin-
guish between HCA and well-differentiated HCC, which is a dif-
ficult challenge especially on needle biopsies. Features that favor 
the possibility of HCC include cytological atypia which is more 
than minimal and patchy, thickened hepatocyte trabeculae, fre-
quent pseudoglandular structures, cholestasis, small cell change 
and loss of reticulin staining (Fig. 5). Caution should be exer-
cised when interpreting reticulin loss, as focal reticulin loss in an 
HCA is acceptable when there is marked steatosis [26]. Conversely, 
well differentiated HCCs show only a partial loss of reticulin 
[27]. Identification of stromal invasion or a nodule-in-nodule 
growth pattern adds more confidence to the diagnosis of HCC. 
In the latter case, the outer and inner nodules are usually com-
posed of HCA and HCC, respectively. The 3-marker panel– 
glypican-3, heat shock protein 70 (HSP70) and GS–which is 
commonly used in the differential diagnosis between dysplastic 
nodules and HCC may be also be helpful for the discrimination 
between HCA and HCC [27-29]. However, as the challenging 
question of “HCA versus HCC” usually arises in the context of 
B-HCAs with strong/moderate β-catenin activation that express 
diffuse GS, the additional expression of glypican-3 and/or HSP70 
would be more helpful in practice [29]. Although HCC often 
demonstrates increased sinusoidal capillarization compared to 
HCA (highlighted by CD34), this is a relative increase without 
definite cut-off values, and therefore CD34 immunohistochem-
istry on its own has limited use in the differential diagnosis. 
The terms “atypical hepatocellular neoplasm (AHN)” and “he-
patocellular neoplasm of uncertain malignant potential (HUMP)” 
have been proposed for hepatocellular neoplasms that demon-
strate features atypical for HCA but insufficient for a confident 
diagnosis of HCC [30-32]. These terms have been coined to 
emphasize the borderline characteristics of these tumors, in-
cluding increased risk for HCC development, and to convey to 
the clinicians the necessity for surgical intervention or at least 
close follow-up. There are currently no widely accepted guide-
lines on when to use these terms, although the following features 




Fig. 4. HNF1A-inactivated hepatocellular adenoma. Diffuse steatosis is seen in the tumor, compared to the surrounding hepatic parenchyme 
(A–C). There is no significant cytological or architectural atypia on higher-power magnification (B). Immunohistochemically, the tumor displays 
loss of liver fatty acid-binding protein expression (C) (dotted line: tumor).
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logical atypia (nuclear atypia, small cell change, pseudoglandular 
structures, loss of reticulin fibers) that is only focal (< 5% of the 
tumor), (2) presence of β-catenin activation or CTNNB1 muta-
tion, and (3) atypical demographic features (e.g., male, age > 50 
years) [30-33]. Of note, Evason et al. [31] demonstrated similar 
cytogenetic alterations to HCC in their series of AHNs, and also 
documented recurrence and metastasis in AHNs with β-catenin 
activation, suggesting that these tumors may actually represent 
an extremely well-differentiated group of HCCs [31]. The pres-
ence of nuclear β-catenin expression, diffuse GS expression, or 
indeterminate diffuse GS expression in hepatocellular neo-
plasms (thus, suggestive of Bex3-HCA) have been suggested as 
criteria for AHN, especially on biopsied specimens [30]. This 
would guide the clinician to surgically resect the nodule in ques-
tion, rather than subjecting the patient to follow up, which is 
important as (1) an overt HCC may be present elsewhere in the 
nodule, and (2) Bex3-HCA have been associated with increased 
risk of HCC development. On resected specimens, the diagnosis 
of B-HCA may be made when the degree of cytoarchitectural 
atypia is insufficient for HCC, although some still prefer to use 
AHN in this setting [30]. 
IHCA vs. FNH vs. mass effect
The presence of ductular reaction, pseudoportal tracts and 
abnormal thick-walled vessels may result in the resemblance of 
IHCA to FNH. There is indeed a significant histological overlap 
between FNH and IHCA, and in fact, lesions previously described 
as telangiectatic FNH have now been reclassified as IHCA on the 
basis of molecular studies [34-36]. Discriminating between 
IHCA and FNH on a needle biopsy is a common difficult chal-
lenge for pathologists. FNH is a reactive polyclonal proliferation 
of hepatocytes in response to vascular abnormalities. Grossly, it 
is a well-demarcated multinodular mass with a central depressed 




Fig. 5. Atypia in hepatocellular neoplasms. When features atypical for hepatocellular adenomas, such as frequent pseudoglandular struc-
tures (A, C–E), nuclear atypia (B, C) and focal reticulin loss (D; inset: preserved reticulin framework for comparison), are identified, the differ-
ential diagnosis should be between atypical hepatocellular neoplasm and well-differentiated hepatocellular carcinoma. When these features 
are only focally present (< 5%), the terminology of atypical hepatocellular neoplasm may be used. Nuclear β-catenin expression is often iden-
tified in such cases (E).
https://jpatholtm.org/ https://doi.org/10.4132/jptm.2021.02.27
178     •  Kim H et al.
fibrous scars and radiating fibrous septa with abnormal vascula-
ture, including eccentrically thickened vascular walls, and marked 
ductular reaction are the typical findings. The hepatocytes 
demonstrate no significant atypia, and the hepatocyte plates are 
1–3 cells thick. The nodularity, fibrous septa and ductular reac-
tion may also be seen in IHCAs; in these situations, immuno-
histochemistry for GS, SAA, and CRP may be helpful. FNH 
demonstrates a remarkable “map-like” GS expression pattern, 
characterized by broad bands of hepatocytes that strongly express 
GS, and these bands appear to anastomose together to produce 
a complex lace-like or map-like architecture (Figs. 3, 6) [37,38]. 
On biopsies, the GS expression appears as patchy broad bands of 
strong GS expression, which contrast with the punctate or linear 
perivenular GS pattern in the adjacent normal parenchyme (Fig. 
6). Nuclear β-catenin staining is absent in FNH, and SAA and 
CRP are usually negative in FNH. Thus, SAA and/or CRP expres-
sion and absence of “map-like” GS expression pattern strongly 
supports a diagnosis of IHCA over FNH.
Mass effect may appear as sinusoidal dilatation and ductular 
reaction in the non-lesional hepatic parenchyme, which may lead 
to an erroneous diagnosis of IHCA [39]. The presence of portal 




Fig. 6. Focal nodular hyperplasia. A typical low power view of a resected case (A). A central stellate scar with radiating fibrous septa is seen, 
containing multiple irregular-shaped vascular structures. When needle biopsy specimens are obtained from the central scar or fibrous septa 
(B, C), it is easy to identify the abnormal vascular channels with varying calibers, shape and irregular walk thickness. Sometimes biopsies in-
clude the peripheral portions without the obvious vascular anomalies; instead there is at least mild hepatocellular nodularity with ductular re-
action (D). Glutamine synthetase immunohistochemistry demonstrates broad bands of GS-expressing hepatocytes (E), which corresponds 
to the map-like pattern in Fig. 3, in contrast to the normal perivenular pattern (arrows). 
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the pathologist to the possibility that the biopsy core was ob-
tained from the perilesional parenchyme and clinicoradiological 
correlation is mandatory. Recognizing the presence of evenly 
spaced portal tracts and central veins, perhaps with the help of 
trichome and GS stains, may also be helpful in suggesting the 
non-neoplastic nature of the biopsied tissue. 
Diagnostic pitfalls in the interpretation of 
immunohistochemical stain results
GS, β-catenin, SAA, CRP, and LFABP are indeed helpful im-
munohistochemical tools for subtyping HCAs and/or discrimi-
nating between HCA and FNH. However, they should also be 
used with care and in the correct context. SAA and CRP expres-
sion have been reported in 17% and ~50% of HCCs, respectively, 
and loss of LFABP expression has been demonstrated in 16%–25% 
of HCCs [40-42]. In addition, as previously mentioned, the back-
ground liver may show focal expression of SAA or CRP, especially 
in the setting of inflammation or hemorrhage; therefore, positivity 
for these markers should be interpreted carefully, taking the his-
tology into account. Moreover, some cirrhotic nodules may express 
SAA and/or CRP, such as in the SAA-positive nodules in alcohol-
ic cirrhosis [43]. Therefore, these markers are not specific for HCA.
GS expression is a well-known component of the 3-marker 
panel (glypican-3, HSP70, and GS) for diagnosing HCCs [28,44]. 
Therefore, immunostains used for subtyping HCAs should only 
be used after an initial impression of HCA has been made, and 
not for distinguishing between HCA and HCC. 
CONCLUSION
Although simply defined as a benign neoplasm of hepatocel-
lular origin, HCA is a heterogeneous entity from both molecu-
lar and histomorphological aspects. The molecular classification 
of HCA has helped to increase our understanding of the biology 
of these tumors. More importantly for pathologists, the molec-
ular classification has also helped to characterize the morpho-
logical and immunohistochemical features in HCAs in detail. 
The association between CTNNB1 mutation status and the 
clinical behavior of HCA brings enormous translational impact, 
as the presence of strong β-catenin activation may influence man-
agement decisions in favor of surgical treatment. As for H-HCAs, 
the identification of individuals with liver adenomatosis composed 
of H-HCA should prompt molecular testing for germline HN-
F1A mutation status, in addition to familial screening for liver 
adenomatosis. It is also possible that additional subtypes of HCA 
will be identified in the future.
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